FILING ANALYSIS · MONDAY, NOVEMBER 9
Immunovant, Inc. IMVT — 8-K: Results of Operations and Financial Condition
positive
Immunovant's IMVT-1402 met the primary endpoint of ACR20 response at Week 28 in a potentially registrational trial for difficult-to-treat rheumatoid arthritis, with 92.5% response rate vs 75.6% for placebo, and the company plans FDA discussions for later this year to determine the path forward
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →